Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...

Dysregulated complement pathways are linked to progression from iAMD to advanced AMD, including NVAMD and GA. Higher systemic levels of C4, C4b, and a reduction in C3 are associated with increased ...

4DMT acquires all world-wide rights to short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc.; technology invented at University of Pennsylvania Announces sCFH as payload for ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA ...

Please provide your email address to receive an email when new articles are posted on . In a first-in-human phase 1/2 study, GT005, an AAV2-based one-time investigational gene therapy, showed ...

ORLANDO, Fla. – New research on sutimlimab, an investigational complement pathway inhibitor under development by Sanofi SA's Bioverativ unit, showed substantial benefits for people with the rare ...

A complement C4 (also known as a complement component 4, or simply C4) is a test to measure the level of C4 proteins you have in your blood. These proteins play a role in how your immune system ...